Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAX8 | Q06710 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.42 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6564631 | 0.88 | EPHX1 (0.47) | HTTMCHR1BACE1BACE2ALDH1A1 | |
| SCHEMBL6565928 | 0.87 | MCHR1 (0.46) | SMN1; SMN2MEN1KMT2AMCHR1 | |
| SCHEMBL6567944 | 0.86 | CASR (0.52) | PAX8KDM4ESMN1; SMN2HTTMEN1 | |
| SCHEMBL6566738 | 0.85 | MCHR1 (0.45) | SMN1; SMN2MEN1KMT2ANAMPTMCHR1 | |
| SCHEMBL6566645 | 0.85 | KDM4E (0.53) | KDM4ESMN1; SMN2HTTMEN1KMT2A | |
| SCHEMBL6565942 | 0.85 | MCHR1 (0.54) | MCHR1 | |
| SCHEMBL6567969 | 0.84 | CASR (0.53) | MEN1KMT2AMCHR1 | |
| SCHEMBL6567876 | 0.84 | RAF1 (0.44) | SMN1; SMN2HTTMEN1KMT2AMCHR1 | |
| SCHEMBL6564619 | 0.83 | MCHR1 (0.49) | MCHR1BACE1BACE2 | |
| SCHEMBL6568064 | 0.83 | MCHR1 (0.46) | MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040259912-A1 | Benzine derivatives, process for preparing the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-12-23 | — | — | US | disclosed |
| EP-1437344-A1 | BENZENE DERIVATIVES,PROCESS FOR PREPARING THE SAME AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2004-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259912-A1 | Benzine derivatives, process for preparing the same and use thereof | HRH4, HRH2, HRH1 | PAX8 1831/4885KDM4E 2962/4885SMN1; SMN2 2126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.